Complement-based Drug Development Summit Europe London, England, UK 20-22 March 2018

Description:
The Complement-based Drug Development Summit Europe is the first industry-dedicated meeting focused on optimizing clinical trial design, efficacy assessment, target identification and expansion beyond orphan diseases.

Across 3 content-packed days, the field's thought leaders from GSK, Novartis, Complement Pharma and many more will be sharing their insight and lessons learned, collectively enabling the community to:

- Analysing Points of Inhibition: Assess the most effective points of complement inhibition for the treatment of individual diseases and the selection of therapeutic approaches for inhibition.
- Optimise Clinical Trial Design: Fine-tune clinical trial design for expansion beyond orphan diseases, advancing patient stratification, targeting, dosing, endpoints and sample handling.
- Standardising Efficacy Assessment: Define the next steps toward achieving standardisation of robust, functional assays in order to accurately determine treatment efficacy.

URLs:
Booking: https://go.evvnt.com/169759-1
Brochure: https://go.evvnt.com/169759-2

Prices:
Gold: Conference and 2 Workshops: GBP 2997,
Silver: Conference and 1 Workshops: GBP 2598,
Bronze: Conference only: GBP 1999,
Workshop: GBP 599

Speakers: Anna Schubart (Novartis), Andrea Tenner (University of California), Michael Holers (University of Colorado), Paul Morgan (Cardiff University), Eva-Maria Nichols (GlaxoSmithKline), Michael Kirschfink (University of Heidelberg), Frank Baas (Complement Pharma), Ashley Frazer-Abel (Exsera Biolabs)

Time: 9:00 am to 4:00 pm